BE2015C066I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C066I2
BE2015C066I2 BE2015C066C BE2015C066C BE2015C066I2 BE 2015C066 I2 BE2015C066 I2 BE 2015C066I2 BE 2015C066 C BE2015C066 C BE 2015C066C BE 2015C066 C BE2015C066 C BE 2015C066C BE 2015C066 I2 BE2015C066 I2 BE 2015C066I2
Authority
BE
Belgium
Application number
BE2015C066C
Other languages
Dutch (nl)
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BE2015C066I2 publication Critical patent/BE2015C066I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2015C066C 2004-03-24 2015-12-09 BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
BE2015C066I2 true BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-08-08

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C066C BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-03-24 2015-12-09

Country Status (31)

Country Link
US (2) US7700103B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1730175B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4833962B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101203403B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1934131B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR048191A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE466022T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005230907C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0509079B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2560487C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110349T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602005020913D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1730175T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2343255T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR15C0085I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1500062I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL178140A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LTC1730175I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92903I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY148656A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300777I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO338055B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ549898A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1730175T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1730175E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2373219C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1730175T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI349036B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005097821A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200607575B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
US7709010B2 (en) 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
EP2479187A1 (en) 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
EP3705133B1 (en) * 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN102268076B (zh) * 2010-07-02 2017-04-26 厦门大学 截短的人乳头瘤病毒52型l1蛋白
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
CN103562392B (zh) 2010-12-03 2016-07-20 Ms技术有限责任公司 植物细胞中草甘膦抗性编码核酸分子的优化表达
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CA2927434C (en) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
WO2021163002A1 (en) 2020-02-14 2021-08-19 Merck Sharp & Dohme Corp. Hpv vaccine
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
US20230118665A1 (en) 2021-08-19 2023-04-20 Merck Sharp & Dohme Llc Novel thermostable lipid nanoparticle and methods of use thereof
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CN1252075A (zh) 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
NZ509610A (en) * 1998-08-14 2002-10-25 Merck & Co Inc Process for purifying human papillomavirus virus-like particles using hydroxyapatite
EP1105157B1 (en) 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
PT1212358E (pt) * 1999-08-25 2005-04-29 Merck & Co Inc Genes sinteticos de papilomavirus humano
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
KR100874552B1 (ko) 2000-07-21 2008-12-16 글락소 그룹 리미티드 코돈-최적화 파필로마 바이러스 서열
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
ES2381964T3 (es) * 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
FR15C0085I2 (fr) 2016-11-25
HUS1500062I1 (hu) 2017-07-28
NL300777I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-29
TWI349036B (en) 2011-09-21
KR20060134120A (ko) 2006-12-27
AU2005230907B2 (en) 2011-05-19
CY2015052I1 (el) 2016-06-22
BRPI0509079B1 (pt) 2020-05-19
CY1110349T1 (el) 2015-04-29
NO338055B1 (no) 2016-07-25
FR15C0085I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-08-01
TW200602490A (en) 2006-01-16
BRPI0509079B8 (pt) 2021-07-06
PT1730175E (pt) 2010-06-25
NL300777I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-29
US7700103B2 (en) 2010-04-20
EP1730175A1 (en) 2006-12-13
CA2560487A1 (en) 2005-10-20
EP1730175B1 (en) 2010-04-28
CN1934131B (zh) 2010-12-29
BRPI0509079A (pt) 2007-08-21
ATE466022T1 (de) 2010-05-15
DK1730175T3 (da) 2010-08-23
JP2007530040A (ja) 2007-11-01
NO20064815L (no) 2006-10-23
LU92903I2 (fr) 2016-03-08
SI1730175T1 (sl) 2010-08-31
LTC1730175I2 (lt) 2017-05-10
NZ549898A (en) 2009-06-26
DE602005020913D1 (de) 2010-06-10
IL178140A (en) 2010-11-30
JP4833962B2 (ja) 2011-12-07
LTPA2015050I1 (lt) 2016-01-11
ZA200607575B (en) 2008-08-27
WO2005097821A1 (en) 2005-10-20
NO2017005I1 (no) 2017-01-20
KR101203403B1 (ko) 2012-11-21
IL178140A0 (en) 2006-12-31
US20080226660A1 (en) 2008-09-18
RU2006137363A (ru) 2008-04-27
AU2005230907A1 (en) 2005-10-20
CN1934131A (zh) 2007-03-21
AR048191A1 (es) 2006-04-05
US20100035818A1 (en) 2010-02-11
CY2015052I2 (el) 2016-06-22
MY148656A (en) 2013-05-15
CA2560487C (en) 2013-01-29
US7744892B2 (en) 2010-06-29
NO2022050I1 (no) 2022-11-30
PL1730175T3 (pl) 2010-09-30
ES2343255T3 (es) 2010-07-27
AU2005230907C1 (en) 2016-07-28
RU2373219C2 (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005147154A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004332738A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005152657A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005024556A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005117608A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005332130A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005030403A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004332731A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004219423A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005083375A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005329779A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004336986A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005199776A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004326091A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005144177A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2004347601A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005041691A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005160107A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005040129A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE502005004146D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005142155A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005221566A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005238248A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)